In quest to interrupt aging, East Bay biotech lands drug, equity deal with Amgen

The company hopes to move into an early-stage clinical trial next year with a drug that could reduce muscle atrophy and increase activity — major attractions for the evolving "aging" drug market.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news